Cargando…

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis

OBJECTIVE: To determine the efficacy of cholinesterase inhibitors (ChEIs) in improving the behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer’s disease (AD). DATA SOURCES: We searched MEDLINE, Cochrane Registry, and the Cumulative Index to Nursing and Allied Health L...

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, Noll, Ayub, Amir, Boustani, Malaz A, Fox, Chris, Farlow, Martin, Maidment, Ian, Howard, Robert
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2682404/
https://www.ncbi.nlm.nih.gov/pubmed/19281064
_version_ 1782167051484266496
author Campbell, Noll
Ayub, Amir
Boustani, Malaz A
Fox, Chris
Farlow, Martin
Maidment, Ian
Howard, Robert
author_facet Campbell, Noll
Ayub, Amir
Boustani, Malaz A
Fox, Chris
Farlow, Martin
Maidment, Ian
Howard, Robert
author_sort Campbell, Noll
collection PubMed
description OBJECTIVE: To determine the efficacy of cholinesterase inhibitors (ChEIs) in improving the behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer’s disease (AD). DATA SOURCES: We searched MEDLINE, Cochrane Registry, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) from 1966 to 2007. We limited our search to English Language, full text, published articles and human studies. DATA EXTRACTION: We included randomized, double-blind, placebo-controlled trials evaluating the efficacy of donepezil, rivastigmine, or galantamine in managing BPSD displayed by AD patients. Using the United States Preventive Services Task Force (USPSTF) guidelines, we critically appraised all studies and included only those with an attrition rate of less than 40%, concealed measurement of the outcomes, and intention to treat analysis of the collected data. All data were imputed into pre-defined evidence based tables and were pooled using the Review Manager 4.2.1 software for data synthesis. RESULTS: We found 12 studies that met our inclusion criteria but only nine of them provided sufficient data for the meta-analysis. Among patients with mild to severe AD and in comparison to placebo, ChEIs as a class had a beneficial effects on reducing BPSD with a standard mean difference (SMD) of −0.10 (95% confidence interval [CI]; −0.18, −0.01) and a weighted mean difference (WMD) of −1.38 neuropsychiatry inventory point (95% CI; −2.30, −0.46). In studies with mild AD patients, the WMD was −1.92 (95% CI; −3.18, −0.66); and in studies with severe AD patients, the WMD was −0.06 (95% CI; −2.12, +0.57). CONCLUSION: Cholinesterase inhibitors lead to a statistical significant reduction in BPSD among patients with AD, yet the clinical relevance of this effect remains unclear.
format Text
id pubmed-2682404
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26824042009-05-20 Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis Campbell, Noll Ayub, Amir Boustani, Malaz A Fox, Chris Farlow, Martin Maidment, Ian Howard, Robert Clin Interv Aging Original Research OBJECTIVE: To determine the efficacy of cholinesterase inhibitors (ChEIs) in improving the behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer’s disease (AD). DATA SOURCES: We searched MEDLINE, Cochrane Registry, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) from 1966 to 2007. We limited our search to English Language, full text, published articles and human studies. DATA EXTRACTION: We included randomized, double-blind, placebo-controlled trials evaluating the efficacy of donepezil, rivastigmine, or galantamine in managing BPSD displayed by AD patients. Using the United States Preventive Services Task Force (USPSTF) guidelines, we critically appraised all studies and included only those with an attrition rate of less than 40%, concealed measurement of the outcomes, and intention to treat analysis of the collected data. All data were imputed into pre-defined evidence based tables and were pooled using the Review Manager 4.2.1 software for data synthesis. RESULTS: We found 12 studies that met our inclusion criteria but only nine of them provided sufficient data for the meta-analysis. Among patients with mild to severe AD and in comparison to placebo, ChEIs as a class had a beneficial effects on reducing BPSD with a standard mean difference (SMD) of −0.10 (95% confidence interval [CI]; −0.18, −0.01) and a weighted mean difference (WMD) of −1.38 neuropsychiatry inventory point (95% CI; −2.30, −0.46). In studies with mild AD patients, the WMD was −1.92 (95% CI; −3.18, −0.66); and in studies with severe AD patients, the WMD was −0.06 (95% CI; −2.12, +0.57). CONCLUSION: Cholinesterase inhibitors lead to a statistical significant reduction in BPSD among patients with AD, yet the clinical relevance of this effect remains unclear. Dove Medical Press 2008-12 2008-12 /pmc/articles/PMC2682404/ /pubmed/19281064 Text en © 2008 Dove Medical Press Limited. All rights reserved
spellingShingle Original Research
Campbell, Noll
Ayub, Amir
Boustani, Malaz A
Fox, Chris
Farlow, Martin
Maidment, Ian
Howard, Robert
Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis
title Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis
title_full Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis
title_fullStr Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis
title_full_unstemmed Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis
title_short Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis
title_sort impact of cholinesterase inhibitors on behavioral and psychological symptoms of alzheimer’s disease: a meta-analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2682404/
https://www.ncbi.nlm.nih.gov/pubmed/19281064
work_keys_str_mv AT campbellnoll impactofcholinesteraseinhibitorsonbehavioralandpsychologicalsymptomsofalzheimersdiseaseametaanalysis
AT ayubamir impactofcholinesteraseinhibitorsonbehavioralandpsychologicalsymptomsofalzheimersdiseaseametaanalysis
AT boustanimalaza impactofcholinesteraseinhibitorsonbehavioralandpsychologicalsymptomsofalzheimersdiseaseametaanalysis
AT foxchris impactofcholinesteraseinhibitorsonbehavioralandpsychologicalsymptomsofalzheimersdiseaseametaanalysis
AT farlowmartin impactofcholinesteraseinhibitorsonbehavioralandpsychologicalsymptomsofalzheimersdiseaseametaanalysis
AT maidmentian impactofcholinesteraseinhibitorsonbehavioralandpsychologicalsymptomsofalzheimersdiseaseametaanalysis
AT howardrobert impactofcholinesteraseinhibitorsonbehavioralandpsychologicalsymptomsofalzheimersdiseaseametaanalysis